Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.

11 Oct 2010

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

24 Sep 2010

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.

23 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer

Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA.

8 Sep 2010

ESPAC-3 trial shows promising results to prevent pancreatic cancer

A major international trial has shown a commonly used chemotherapy drug is as effective at helping prevent pancreatic cancer returning after surgery as the more expensive standard chemotherapy treatment, reveals a study published in the Journal of the American Medical Association today (Wednesday).

8 Sep 2010

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study published in the September edition of the Journal of Thoracic Oncology, analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay.

2 Sep 2010

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat.

2 Sep 2010

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

27 Aug 2010

Combination of 2 FDA approved drugs eliminate HIV infection

Researchers at the University of Minnesota Academic Health Center have identified two drugs that, when combined, may serve as an effective treatment for HIV.

21 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Threshold Pharmaceuticals reports net loss of $0.3M for second-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2010.

6 Aug 2010

Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials

Cornerstone Pharmaceuticals, Inc. today announced the addition of Mary Crowley Cancer Research Centers to its roster of sites for its ongoing Phase I/II clinical trials of its first-in-class anti-cancer agent, CPI-613. Cornerstone is a leader in the discovery and development of cancer therapies that capitalize upon and disrupt the unique metabolic processes of cancer cells.

6 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

4 Aug 2010

U.S. Court of Appeals rules against Eli Lily's claims in Gemzar patent lawsuit

Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.

29 Jul 2010

Eli Lilly disagrees with U.S. Court of Appeals ruling on Gemzar method-of-use patent

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has upheld a prior ruling by the U.S. District Court for the Eastern District of Michigan that Gemzar's method-of-use patent is invalid.

29 Jul 2010

Preclinical results of TH-302 presented at AACR Translational Cancer Medicine Meeting

Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.

13 Jul 2010

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

12 Jul 2010

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.